Specialized tissue-based test that surveys hotspot regions of 50 oncogenes / tumor suppressor genes that are associated with current Oncology drugs and treatment protocols of multiple cancers.
Who should opt for Hotspot Test?
- Patients with advanced (Stages 2,3 and 4: metastatic cancers) colorectal & lung carcinoma and melanoma.
- Patients with rare type of cancers
- Prior to starting new generation drugs to treat cancer patients having poor response to initial treatment
What makes Hotspot Test special?
- Wider coverage to detect clinically actionable genetic alterations in patients with advanced solid tumor cancer
- Identify BRAF variants & specific EGFR variants, KRAS, BRAF, PIK3CA, and AKT mutant versus wild type reporting (as clinically indicated)
- Identify any other clinically-relevant variants in the less mutated genes
- Requires very less sample (10ng of DNA), from cytology specimen (like fine needle aspirates) or formalin-fixed paraffin-embedded biopsy tissue.
- Enables personalized therapeutic option with access to conventional therapy and clinical trial of new drugs.
Core Genes - 50
- ABL1
- AKT1
- ALK
- APC
- ATM
- BRAF
- CDH1
- CDKN2A
- CSF1R
- CTNNB1
- EGFR
- ERBB2
- ERBB4
- EZH2
- FBXW7
- FGFR1
- FGFR2
- FGFR3
- FLT3
- GNA11
- GNAS
- GNAQ
- HNF1A
- HRAS
- IDH1
- JAK2
- JAK3
- IDH2
- KDR
- KIT
- KRAS
- MET
- MLH1
- MPL
- NOTCH1
- NPM1
- NRAS
- PDGFRA
- PIK3CA
- PTEN
- PTPN11
- RB1
- RET
- SMAD4
- SMARCB1
- SMO
- SRC
- STK11
- TP53
- VHL
